# 2026-00325: FDA Embraces Bayesian Math to Fast-Track Drug Approvals

2026-00325, Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-01-12, effective Submit either electronic or written comments on the draft guidance by March 13, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance. (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-00325
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-00325
- Title: Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products; Draft Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 1190
- Published: 2026-01-12
- Effective: Submit either electronic or written comments on the draft guidance by March 13, 2026 to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance.
- Comments close: 2026-03-13
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Embraces Bayesian Math to Fast-Track Drug Approvals

## Summary

The FDA just dropped a draft guide to help drug makers use Bayesian methods in clinical trials, making it easier to prove a drug’s safety and effectiveness. This affects companies testing new drugs and biologics, offering a fresh, smarter way to analyze trial results. Comments are open until March 13, 2026, so get your thoughts in early to shape the final rules—this could speed up approvals and save money down the road!

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products." This document provides guidance on the appropriate use of Bayesian methods in clinical trials. The primary focus is on the use of Bayesian methods to support primary inference in pivotal clinical trials designed to support the effectiveness and safety of drug and biological products.

## Effects PRIA read

- Draft FDA guide allows Bayesian trials: benefit, medium. If you are a sponsor or applicant (for INDs, NDAs, BLAs, or supplemental applications), the FDA published a draft guidance titled “Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products” that explains how to use Bayesian methods to support primary inference in pivotal clinic…
- Informative priors and external data use: benefit, medium. The draft guidance includes detailed considerations for using an informative prior to borrow external information in the primary analysis of a prospective trial. It also provides recommendations on choice of success criteria, evaluation of trial operating characteristics, and determination of the p…
- Comment window and cost comments: benefit, low. FDA invites electronic or written comments on the draft guidance and asks that they be submitted by March 13, 2026 so the Agency can consider them before preparing a final version. FDA also states it will consider comments on costs or cost savings that the guidance may generate in its development o…

## Related documents

- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27
- [2026-20727](https://policyrisk.com/federal-register/2026-20727): Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorgani…, 2026-10-09

## Sources
- [2026-00325 on federalregister.gov](https://www.federalregister.gov/documents/2026/01/12/2026-00325/use-of-bayesian-methodology-in-clinical-trials-of-drug-and-biological-products-draft-guidance-for)
- [2026-00325 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-01-12/pdf/2026-00325.pdf)

## Related
- [Previous: 2026-00324, Agency Information Collection Activities; Proposed Collection; Comment Request;…](https://policyrisk.com/federal-register/2026-00324)
- [Next: 2026-00328, Withdrawal of Joint Statement on the Equal Credit Opportunity Act and Noncitize…](https://policyrisk.com/federal-register/2026-00328)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-00325 (as of 2026-06-08).